nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—CYP1B1—Mitoxantrone—sarcoma	0.127	0.178	CbGbCtD
Lansoprazole—CYP1A1—Dacarbazine—sarcoma	0.0716	0.101	CbGbCtD
Lansoprazole—ABCG2—Dactinomycin—sarcoma	0.0672	0.0945	CbGbCtD
Lansoprazole—ABCG2—Mitoxantrone—sarcoma	0.0602	0.0846	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—sarcoma	0.0544	0.0765	CbGbCtD
Lansoprazole—ABCG2—Vincristine—sarcoma	0.0414	0.0582	CbGbCtD
Lansoprazole—ABCG2—Etoposide—sarcoma	0.0379	0.0533	CbGbCtD
Lansoprazole—CYP1A2—Dacarbazine—sarcoma	0.032	0.0449	CbGbCtD
Lansoprazole—CYP3A4—Thiotepa—sarcoma	0.0302	0.0425	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—sarcoma	0.0259	0.0364	CbGbCtD
Lansoprazole—ABCB1—Dactinomycin—sarcoma	0.0242	0.0341	CbGbCtD
Lansoprazole—ABCB1—Mitoxantrone—sarcoma	0.0217	0.0305	CbGbCtD
Lansoprazole—CYP2C8—Etoposide—sarcoma	0.0202	0.0284	CbGbCtD
Lansoprazole—CYP1A2—Etoposide—sarcoma	0.0156	0.022	CbGbCtD
Lansoprazole—ABCB1—Vincristine—sarcoma	0.0149	0.021	CbGbCtD
Lansoprazole—ABCB1—Etoposide—sarcoma	0.0137	0.0192	CbGbCtD
Lansoprazole—CYP3A4—Mitoxantrone—sarcoma	0.013	0.0183	CbGbCtD
Lansoprazole—ABCB1—Doxorubicin—sarcoma	0.00933	0.0131	CbGbCtD
Lansoprazole—CYP3A4—Vincristine—sarcoma	0.00894	0.0126	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—sarcoma	0.00879	0.0124	CbGbCtD
Lansoprazole—CYP3A4—Etoposide—sarcoma	0.0082	0.0115	CbGbCtD
Lansoprazole—ATP4A—larynx—sarcoma	0.00775	0.214	CbGeAlD
Lansoprazole—CYP3A4—Doxorubicin—sarcoma	0.00559	0.00786	CbGbCtD
Lansoprazole—ATP4B—liver—sarcoma	0.00182	0.0504	CbGeAlD
Lansoprazole—ATP4A—hematopoietic system—sarcoma	0.00153	0.0423	CbGeAlD
Lansoprazole—MAPT—LKB1 signaling events—EZR—sarcoma	0.00151	0.0535	CbGpPWpGaD
Lansoprazole—ATP4A—connective tissue—sarcoma	0.00147	0.0408	CbGeAlD
Lansoprazole—MAPT—tendon—sarcoma	0.00136	0.0377	CbGeAlD
Lansoprazole—MAPT—testis—sarcoma	0.00113	0.0312	CbGeAlD
Lansoprazole—CYP1B1—mammary gland—sarcoma	0.000999	0.0277	CbGeAlD
Lansoprazole—MAPT—Notch Signaling Pathway—TLE1—sarcoma	0.000995	0.0352	CbGpPWpGaD
Lansoprazole—CYP4A11—liver—sarcoma	0.000983	0.0272	CbGeAlD
Lansoprazole—MAPT—Signaling mediated by p38-gamma and p38-delta—CCND1—sarcoma	0.000963	0.034	CbGpPWpGaD
Lansoprazole—MAPT—Kit receptor signaling pathway—MITF—sarcoma	0.00089	0.0315	CbGpPWpGaD
Lansoprazole—ATP4A—testis—sarcoma	0.000838	0.0232	CbGeAlD
Lansoprazole—MAPT—lymph node—sarcoma	0.000818	0.0226	CbGeAlD
Lansoprazole—ATP4A—liver—sarcoma	0.000792	0.0219	CbGeAlD
Lansoprazole—CYP2C8—mammary gland—sarcoma	0.000765	0.0212	CbGeAlD
Lansoprazole—CYP2C18—FOXA1 transcription factor network—COL18A1—sarcoma	0.000728	0.0257	CbGpPWpGaD
Lansoprazole—CYP2C9—mammary gland—sarcoma	0.00068	0.0188	CbGeAlD
Lansoprazole—MAPT—Kit receptor signaling pathway—PLCG1—sarcoma	0.000678	0.0239	CbGpPWpGaD
Lansoprazole—CYP2C18—liver—sarcoma	0.000651	0.018	CbGeAlD
Lansoprazole—MAPT—LPA receptor mediated events—PLCG1—sarcoma	0.000635	0.0224	CbGpPWpGaD
Lansoprazole—CYP1B1—hematopoietic system—sarcoma	0.000609	0.0168	CbGeAlD
Lansoprazole—CYP1B1—connective tissue—sarcoma	0.000586	0.0162	CbGeAlD
Lansoprazole—CYP1B1—smooth muscle tissue—sarcoma	0.000536	0.0148	CbGeAlD
Lansoprazole—CYP2C19—hematopoietic system—sarcoma	0.000534	0.0148	CbGeAlD
Lansoprazole—MAPT—Copper homeostasis—FOXO1—sarcoma	0.000532	0.0188	CbGpPWpGaD
Lansoprazole—CYP1B1—skin of body—sarcoma	0.000529	0.0146	CbGeAlD
Lansoprazole—ABCG2—myometrium—sarcoma	0.000528	0.0146	CbGeAlD
Lansoprazole—ABCG2—seminal vesicle—sarcoma	0.000477	0.0132	CbGeAlD
Lansoprazole—CYP2C8—hematopoietic system—sarcoma	0.000466	0.0129	CbGeAlD
Lansoprazole—CYP1B1—uterus—sarcoma	0.00046	0.0127	CbGeAlD
Lansoprazole—CYP4A11—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000454	0.016	CbGpPWpGaD
Lansoprazole—MAPT—LKB1 signaling events—CREB1—sarcoma	0.000449	0.0159	CbGpPWpGaD
Lansoprazole—CYP1A2—hematopoietic system—sarcoma	0.000436	0.0121	CbGeAlD
Lansoprazole—CYP1A1—hematopoietic system—sarcoma	0.00043	0.0119	CbGeAlD
Lansoprazole—CYP1B1—lymphoid tissue—sarcoma	0.000429	0.0119	CbGeAlD
Lansoprazole—CYP2C9—hematopoietic system—sarcoma	0.000414	0.0115	CbGeAlD
Lansoprazole—CYP1B1—tendon—sarcoma	0.000403	0.0112	CbGeAlD
Lansoprazole—CYP1A1—skin of body—sarcoma	0.000374	0.0104	CbGeAlD
Lansoprazole—MAPT—Kit receptor signaling pathway—KIT—sarcoma	0.000366	0.0129	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.000364	0.0128	CbGpPWpGaD
Lansoprazole—MAPT—Apoptotic cleavage of cellular proteins—CTNNB1—sarcoma	0.000354	0.0125	CbGpPWpGaD
Lansoprazole—MAPT—IL-5 Signaling Pathway—IL2—sarcoma	0.000352	0.0124	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000348	0.0123	CbGpPWpGaD
Lansoprazole—ABCG2—uterus—sarcoma	0.000342	0.00948	CbGeAlD
Lansoprazole—MAPT—IL-5 Signaling Pathway—JUN—sarcoma	0.000342	0.0121	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—IL2—sarcoma	0.000338	0.012	CbGpPWpGaD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000337	0.0119	CbGpPWpGaD
Lansoprazole—CYP1B1—testis—sarcoma	0.000334	0.00923	CbGeAlD
Lansoprazole—MAPT—BDNF signaling pathway—PLCG1—sarcoma	0.000332	0.0117	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—JUN—sarcoma	0.000329	0.0116	CbGpPWpGaD
Lansoprazole—CYP1A1—cardiac atrium—sarcoma	0.000327	0.00904	CbGeAlD
Lansoprazole—CYP1A1—uterus—sarcoma	0.000325	0.009	CbGeAlD
Lansoprazole—MAPT—Copper homeostasis—MDM2—sarcoma	0.000319	0.0113	CbGpPWpGaD
Lansoprazole—CYP1B1—Melatonin metabolism and effects—FOXO1—sarcoma	0.000317	0.0112	CbGpPWpGaD
Lansoprazole—CYP3A4—hematopoietic system—sarcoma	0.000316	0.00874	CbGeAlD
Lansoprazole—CYP1B1—liver—sarcoma	0.000315	0.00873	CbGeAlD
Lansoprazole—CYP1B1—Estrogen Receptor Pathway—JUN—sarcoma	0.000314	0.0111	CbGpPWpGaD
Lansoprazole—CYP2D6—hematopoietic system—sarcoma	0.000311	0.0086	CbGeAlD
Lansoprazole—MAPT—LPA receptor mediated events—MMP2—sarcoma	0.000304	0.0107	CbGpPWpGaD
Lansoprazole—ABCG2—bone marrow—sarcoma	0.000291	0.00804	CbGeAlD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000286	0.0101	CbGpPWpGaD
Lansoprazole—CYP4A11—PPAR Alpha Pathway—CCND1—sarcoma	0.00028	0.0099	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—CCND1—sarcoma	0.000278	0.00982	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—JUN—sarcoma	0.000277	0.0098	CbGpPWpGaD
Lansoprazole—CYP2C19—liver—sarcoma	0.000277	0.00766	CbGeAlD
Lansoprazole—MAPT—Apoptotic execution phase—CTNNB1—sarcoma	0.000275	0.00973	CbGpPWpGaD
Lansoprazole—MAPT—IL-5 Signaling Pathway—MYC—sarcoma	0.000275	0.00972	CbGpPWpGaD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000271	0.00959	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—MYC—sarcoma	0.000265	0.00935	CbGpPWpGaD
Lansoprazole—ABCB1—myometrium—sarcoma	0.00026	0.00721	CbGeAlD
Lansoprazole—MAPT—LKB1 signaling events—MYC—sarcoma	0.00026	0.00917	CbGpPWpGaD
Lansoprazole—CYP2C8—testis—sarcoma	0.000256	0.00707	CbGeAlD
Lansoprazole—MAPT—IL-5 Signaling Pathway—KRAS—sarcoma	0.000254	0.00898	CbGpPWpGaD
Lansoprazole—ABCB1—embryo—sarcoma	0.00025	0.00693	CbGeAlD
Lansoprazole—ABCG2—testis—sarcoma	0.000248	0.00688	CbGeAlD
Lansoprazole—MAPT—Notch Signaling Pathway—CCND1—sarcoma	0.000245	0.00864	CbGpPWpGaD
Lansoprazole—CYP1B1—lymph node—sarcoma	0.000242	0.00669	CbGeAlD
Lansoprazole—CYP2C8—liver—sarcoma	0.000242	0.00669	CbGeAlD
Lansoprazole—ABCB1—seminal vesicle—sarcoma	0.000235	0.00651	CbGeAlD
Lansoprazole—MAPT—LPA receptor mediated events—JUN—sarcoma	0.000235	0.0083	CbGpPWpGaD
Lansoprazole—ABCG2—liver—sarcoma	0.000235	0.0065	CbGeAlD
Lansoprazole—CYP1A2—liver—sarcoma	0.000226	0.00626	CbGeAlD
Lansoprazole—MAPT—Kit receptor signaling pathway—SRC—sarcoma	0.000225	0.00795	CbGpPWpGaD
Lansoprazole—CYP4A11—PPAR Alpha Pathway—MYC—sarcoma	0.000225	0.00794	CbGpPWpGaD
Lansoprazole—ABCB1—hematopoietic system—sarcoma	0.000224	0.00619	CbGeAlD
Lansoprazole—CYP1A1—liver—sarcoma	0.000223	0.00617	CbGeAlD
Lansoprazole—MAPT—Notch Signaling Pathway—SRC—sarcoma	0.000219	0.00774	CbGpPWpGaD
Lansoprazole—CYP2C9—liver—sarcoma	0.000215	0.00594	CbGeAlD
Lansoprazole—MAPT—LKB1 signaling events—TP53—sarcoma	0.000213	0.00753	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—SRC—sarcoma	0.000211	0.00745	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-2-alpha transcription factor network—KDR—sarcoma	0.00021	0.00741	CbGpPWpGaD
Lansoprazole—MAPT—MAPK Signaling Pathway—PDGFRB—sarcoma	0.000208	0.00734	CbGpPWpGaD
Lansoprazole—MAPT—IL-2 Signaling Pathway—HRAS—sarcoma	0.000208	0.00734	CbGpPWpGaD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000202	0.00714	CbGpPWpGaD
Lansoprazole—MAPT—Notch Signaling Pathway—MYC—sarcoma	0.000196	0.00693	CbGpPWpGaD
Lansoprazole—CYP1A1—Melatonin metabolism and effects—FOXO1—sarcoma	0.000195	0.00689	CbGpPWpGaD
Lansoprazole—CYP1A1—Estrogen Receptor Pathway—JUN—sarcoma	0.000193	0.00683	CbGpPWpGaD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000189	0.00668	CbGpPWpGaD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000186	0.00657	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—EGFR—sarcoma	0.000185	0.00653	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000185	0.00652	CbGpPWpGaD
Lansoprazole—MAPT—Copper homeostasis—TP53—sarcoma	0.000183	0.00647	CbGpPWpGaD
Lansoprazole—ABCG2—lymph node—sarcoma	0.00018	0.00498	CbGeAlD
Lansoprazole—CYP2C18—Tryptophan metabolism—MDM2—sarcoma	0.000178	0.00629	CbGpPWpGaD
Lansoprazole—CYP1A1—lymph node—sarcoma	0.000171	0.00473	CbGeAlD
Lansoprazole—MAPT—BDNF signaling pathway—CREB1—sarcoma	0.000171	0.00603	CbGpPWpGaD
Lansoprazole—CYP2D6—testis—sarcoma	0.00017	0.00471	CbGeAlD
Lansoprazole—ABCB1—uterus—sarcoma	0.000169	0.00467	CbGeAlD
Lansoprazole—CYP3A4—liver—sarcoma	0.000164	0.00453	CbGeAlD
Lansoprazole—CYP2D6—liver—sarcoma	0.000161	0.00446	CbGeAlD
Lansoprazole—CYP2C18—FOXA1 transcription factor network—JUN—sarcoma	0.00016	0.00567	CbGpPWpGaD
Lansoprazole—CYP2C19—Melatonin metabolism and effects—FOXO1—sarcoma	0.00016	0.00564	CbGpPWpGaD
Lansoprazole—MAPT—Kit receptor signaling pathway—HRAS—sarcoma	0.000158	0.00559	CbGpPWpGaD
Lansoprazole—ABCB1—lymphoid tissue—sarcoma	0.000157	0.00436	CbGeAlD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.000155	0.00546	CbGpPWpGaD
Lansoprazole—MAPT—LPA receptor mediated events—HRAS—sarcoma	0.000148	0.00524	CbGpPWpGaD
Lansoprazole—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000147	0.00521	CbGpPWpGaD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000147	0.00518	CbGpPWpGaD
Lansoprazole—CYP2D6—Melatonin metabolism and effects—FOXO1—sarcoma	0.000147	0.00518	CbGpPWpGaD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	0.000144	0.0051	CbGpPWpGaD
Lansoprazole—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000144	0.00508	CbGpPWpGaD
Lansoprazole—ABCB1—bone marrow—sarcoma	0.000143	0.00397	CbGeAlD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000136	0.00481	CbGpPWpGaD
Lansoprazole—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000134	0.00475	CbGpPWpGaD
Lansoprazole—CYP1B1—Tryptophan metabolism—MDM2—sarcoma	0.000131	0.00464	CbGpPWpGaD
Lansoprazole—MAPT—Alzheimers Disease—TP53—sarcoma	0.000131	0.00463	CbGpPWpGaD
Lansoprazole—Dermatitis—Thiotepa—sarcoma	0.000129	0.000576	CcSEcCtD
Lansoprazole—Headache—Thiotepa—sarcoma	0.000128	0.000573	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000128	0.000572	CcSEcCtD
Lansoprazole—Rash—Dactinomycin—sarcoma	0.000128	0.000572	CcSEcCtD
Lansoprazole—Decreased appetite—Etoposide—sarcoma	0.000128	0.000571	CcSEcCtD
Lansoprazole—Pancytopenia—Doxorubicin—sarcoma	0.000128	0.000569	CcSEcCtD
Lansoprazole—Renal failure—Epirubicin—sarcoma	0.000127	0.000567	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Etoposide—sarcoma	0.000127	0.000567	CcSEcCtD
Lansoprazole—Asthenia—Mitoxantrone—sarcoma	0.000127	0.000566	CcSEcCtD
Lansoprazole—Fatigue—Etoposide—sarcoma	0.000127	0.000566	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Epirubicin—sarcoma	0.000127	0.000566	CcSEcCtD
Lansoprazole—Jaundice—Epirubicin—sarcoma	0.000126	0.000562	CcSEcCtD
Lansoprazole—Stomatitis—Epirubicin—sarcoma	0.000126	0.000562	CcSEcCtD
Lansoprazole—Constipation—Etoposide—sarcoma	0.000126	0.000561	CcSEcCtD
Lansoprazole—Pain—Etoposide—sarcoma	0.000126	0.000561	CcSEcCtD
Lansoprazole—Conjunctivitis—Epirubicin—sarcoma	0.000126	0.000561	CcSEcCtD
Lansoprazole—Urinary tract infection—Epirubicin—sarcoma	0.000126	0.000561	CcSEcCtD
Lansoprazole—Dysuria—Doxorubicin—sarcoma	0.000126	0.00056	CcSEcCtD
Lansoprazole—Neutropenia—Doxorubicin—sarcoma	0.000126	0.00056	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000125	0.000557	CcSEcCtD
Lansoprazole—Diarrhoea—Vincristine—sarcoma	0.000124	0.000555	CcSEcCtD
Lansoprazole—CYP1A2—Melatonin metabolism and effects—FOXO1—sarcoma	0.000124	0.00439	CbGpPWpGaD
Lansoprazole—Sweating—Epirubicin—sarcoma	0.000124	0.000553	CcSEcCtD
Lansoprazole—Pollakiuria—Doxorubicin—sarcoma	0.000124	0.000553	CcSEcCtD
Lansoprazole—Haematuria—Epirubicin—sarcoma	0.000123	0.00055	CcSEcCtD
Lansoprazole—CYP1A2—Estrogen Receptor Pathway—JUN—sarcoma	0.000123	0.00435	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—JUN—sarcoma	0.000123	0.00434	CbGpPWpGaD
Lansoprazole—Photosensitivity reaction—Doxorubicin—sarcoma	0.000123	0.000547	CcSEcCtD
Lansoprazole—ABCB1—testis—sarcoma	0.000123	0.00339	CbGeAlD
Lansoprazole—Hepatobiliary disease—Epirubicin—sarcoma	0.000122	0.000546	CcSEcCtD
Lansoprazole—Weight increased—Doxorubicin—sarcoma	0.000122	0.000545	CcSEcCtD
Lansoprazole—Epistaxis—Epirubicin—sarcoma	0.000122	0.000544	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—CTNNB1—sarcoma	0.000122	0.00431	CbGpPWpGaD
Lansoprazole—Nausea—Thiotepa—sarcoma	0.000122	0.000543	CcSEcCtD
Lansoprazole—Sinusitis—Epirubicin—sarcoma	0.000121	0.000541	CcSEcCtD
Lansoprazole—Feeling abnormal—Etoposide—sarcoma	0.000121	0.000541	CcSEcCtD
Lansoprazole—Hyperglycaemia—Doxorubicin—sarcoma	0.000121	0.00054	CcSEcCtD
Lansoprazole—Diarrhoea—Mitoxantrone—sarcoma	0.000121	0.00054	CcSEcCtD
Lansoprazole—Nausea—Dactinomycin—sarcoma	0.000121	0.000539	CcSEcCtD
Lansoprazole—Agranulocytosis—Epirubicin—sarcoma	0.000121	0.000538	CcSEcCtD
Lansoprazole—Pneumonia—Doxorubicin—sarcoma	0.00012	0.000537	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Etoposide—sarcoma	0.00012	0.000537	CcSEcCtD
Lansoprazole—Dizziness—Vincristine—sarcoma	0.00012	0.000536	CcSEcCtD
Lansoprazole—Infestation NOS—Doxorubicin—sarcoma	0.00012	0.000534	CcSEcCtD
Lansoprazole—Infestation—Doxorubicin—sarcoma	0.00012	0.000534	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000119	0.000529	CcSEcCtD
Lansoprazole—Bradycardia—Epirubicin—sarcoma	0.000118	0.000527	CcSEcCtD
Lansoprazole—Renal failure—Doxorubicin—sarcoma	0.000118	0.000525	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Doxorubicin—sarcoma	0.000117	0.000523	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000117	0.00415	CbGpPWpGaD
Lansoprazole—Urticaria—Etoposide—sarcoma	0.000117	0.000522	CcSEcCtD
Lansoprazole—Jaundice—Doxorubicin—sarcoma	0.000117	0.00052	CcSEcCtD
Lansoprazole—Stomatitis—Doxorubicin—sarcoma	0.000117	0.00052	CcSEcCtD
Lansoprazole—Rhinitis—Epirubicin—sarcoma	0.000116	0.000519	CcSEcCtD
Lansoprazole—Body temperature increased—Etoposide—sarcoma	0.000116	0.000519	CcSEcCtD
Lansoprazole—Abdominal pain—Etoposide—sarcoma	0.000116	0.000519	CcSEcCtD
Lansoprazole—Conjunctivitis—Doxorubicin—sarcoma	0.000116	0.000519	CcSEcCtD
Lansoprazole—Urinary tract infection—Doxorubicin—sarcoma	0.000116	0.000519	CcSEcCtD
Lansoprazole—Hepatitis—Epirubicin—sarcoma	0.000116	0.000518	CcSEcCtD
Lansoprazole—ABCB1—liver—sarcoma	0.000116	0.00321	CbGeAlD
Lansoprazole—Hypoaesthesia—Epirubicin—sarcoma	0.000116	0.000515	CcSEcCtD
Lansoprazole—Vomiting—Vincristine—sarcoma	0.000116	0.000515	CcSEcCtD
Lansoprazole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—sarcoma	0.000116	0.00408	CbGpPWpGaD
Lansoprazole—Pharyngitis—Epirubicin—sarcoma	0.000115	0.000514	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—CTNNB1—sarcoma	0.000115	0.00406	CbGpPWpGaD
Lansoprazole—Sweating—Doxorubicin—sarcoma	0.000115	0.000512	CcSEcCtD
Lansoprazole—Urinary tract disorder—Epirubicin—sarcoma	0.000115	0.000512	CcSEcCtD
Lansoprazole—Rash—Vincristine—sarcoma	0.000115	0.000511	CcSEcCtD
Lansoprazole—Dermatitis—Vincristine—sarcoma	0.000115	0.000511	CcSEcCtD
Lansoprazole—Oedema peripheral—Epirubicin—sarcoma	0.000114	0.00051	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—sarcoma	0.000114	0.000509	CcSEcCtD
Lansoprazole—Connective tissue disorder—Epirubicin—sarcoma	0.000114	0.000509	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000114	0.00403	CbGpPWpGaD
Lansoprazole—Urethral disorder—Epirubicin—sarcoma	0.000114	0.000508	CcSEcCtD
Lansoprazole—Headache—Vincristine—sarcoma	0.000114	0.000508	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—sarcoma	0.000113	0.000505	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—sarcoma	0.000113	0.000504	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000113	0.00398	CbGpPWpGaD
Lansoprazole—Vomiting—Mitoxantrone—sarcoma	0.000113	0.000502	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—sarcoma	0.000112	0.000501	CcSEcCtD
Lansoprazole—Visual impairment—Epirubicin—sarcoma	0.000112	0.000499	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—sarcoma	0.000112	0.000498	CcSEcCtD
Lansoprazole—Rash—Mitoxantrone—sarcoma	0.000112	0.000498	CcSEcCtD
Lansoprazole—Dermatitis—Mitoxantrone—sarcoma	0.000112	0.000497	CcSEcCtD
Lansoprazole—Headache—Mitoxantrone—sarcoma	0.000111	0.000494	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—SRC—sarcoma	0.00011	0.00389	CbGpPWpGaD
Lansoprazole—Erythema multiforme—Epirubicin—sarcoma	0.00011	0.00049	CcSEcCtD
Lansoprazole—Bradycardia—Doxorubicin—sarcoma	0.000109	0.000488	CcSEcCtD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000109	0.00386	CbGpPWpGaD
Lansoprazole—Eye disorder—Epirubicin—sarcoma	0.000109	0.000484	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—JUN—sarcoma	0.000109	0.00384	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Etoposide—sarcoma	0.000108	0.000484	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—sarcoma	0.000108	0.000483	CcSEcCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.000108	0.00382	CbGpPWpGaD
Lansoprazole—Nausea—Vincristine—sarcoma	0.000108	0.000481	CcSEcCtD
Lansoprazole—Cardiac disorder—Epirubicin—sarcoma	0.000108	0.000481	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—sarcoma	0.000108	0.000481	CcSEcCtD
Lansoprazole—Hepatitis—Doxorubicin—sarcoma	0.000108	0.000479	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—sarcoma	0.000107	0.000477	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—sarcoma	0.000107	0.000476	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—sarcoma	0.000106	0.000473	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—sarcoma	0.000106	0.000472	CcSEcCtD
Lansoprazole—Asthenia—Etoposide—sarcoma	0.000106	0.000471	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—sarcoma	0.000106	0.000471	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—sarcoma	0.000105	0.00047	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—sarcoma	0.000105	0.00047	CcSEcCtD
Lansoprazole—Nausea—Mitoxantrone—sarcoma	0.000105	0.000469	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—sarcoma	0.000105	0.000468	CcSEcCtD
Lansoprazole—Mediastinal disorder—Epirubicin—sarcoma	0.000105	0.000467	CcSEcCtD
Lansoprazole—Chills—Epirubicin—sarcoma	0.000104	0.000465	CcSEcCtD
Lansoprazole—Pruritus—Etoposide—sarcoma	0.000104	0.000464	CcSEcCtD
Lansoprazole—Arrhythmia—Epirubicin—sarcoma	0.000104	0.000463	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—sarcoma	0.000104	0.000462	CcSEcCtD
Lansoprazole—Alopecia—Epirubicin—sarcoma	0.000103	0.000458	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000102	0.00362	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000102	0.00362	CbGpPWpGaD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000102	0.00361	CbGpPWpGaD
Lansoprazole—Mental disorder—Epirubicin—sarcoma	0.000102	0.000454	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—sarcoma	0.000102	0.000453	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—sarcoma	0.000101	0.000451	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—sarcoma	0.000101	0.000451	CcSEcCtD
Lansoprazole—Diarrhoea—Etoposide—sarcoma	0.000101	0.000449	CcSEcCtD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000101	0.00355	CbGpPWpGaD
Lansoprazole—Eye disorder—Doxorubicin—sarcoma	0.0001	0.000448	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—sarcoma	0.0001	0.000447	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—sarcoma	9.98e-05	0.000445	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	9.97e-05	0.00352	CbGpPWpGaD
Lansoprazole—Flatulence—Epirubicin—sarcoma	9.97e-05	0.000444	CcSEcCtD
Lansoprazole—Tension—Epirubicin—sarcoma	9.93e-05	0.000442	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—sarcoma	9.9e-05	0.000442	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	9.85e-05	0.00348	CbGpPWpGaD
Lansoprazole—Nervousness—Epirubicin—sarcoma	9.82e-05	0.000438	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	9.82e-05	0.00347	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	9.8e-05	0.00346	CbGpPWpGaD
Lansoprazole—Back pain—Epirubicin—sarcoma	9.78e-05	0.000436	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—sarcoma	9.75e-05	0.000435	CcSEcCtD
Lansoprazole—Dizziness—Etoposide—sarcoma	9.74e-05	0.000434	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—sarcoma	9.72e-05	0.000434	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	9.72e-05	0.00344	CbGpPWpGaD
Lansoprazole—Immune system disorder—Doxorubicin—sarcoma	9.71e-05	0.000433	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—sarcoma	9.69e-05	0.000432	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—sarcoma	9.65e-05	0.00043	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—sarcoma	9.6e-05	0.000428	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—sarcoma	9.53e-05	0.000425	CcSEcCtD
Lansoprazole—Alopecia—Doxorubicin—sarcoma	9.5e-05	0.000424	CcSEcCtD
Lansoprazole—Mental disorder—Doxorubicin—sarcoma	9.42e-05	0.00042	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—sarcoma	9.38e-05	0.000418	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—NRAS—sarcoma	9.37e-05	0.00331	CbGpPWpGaD
Lansoprazole—Vomiting—Etoposide—sarcoma	9.36e-05	0.000417	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—sarcoma	9.36e-05	0.000417	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—sarcoma	9.36e-05	0.000417	CcSEcCtD
Lansoprazole—Anaemia—Epirubicin—sarcoma	9.35e-05	0.000417	CcSEcCtD
Lansoprazole—Agitation—Epirubicin—sarcoma	9.29e-05	0.000414	CcSEcCtD
Lansoprazole—Rash—Etoposide—sarcoma	9.28e-05	0.000414	CcSEcCtD
Lansoprazole—Dermatitis—Etoposide—sarcoma	9.28e-05	0.000414	CcSEcCtD
Lansoprazole—Headache—Etoposide—sarcoma	9.23e-05	0.000411	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—sarcoma	9.22e-05	0.000411	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—sarcoma	9.18e-05	0.000409	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—MYC—sarcoma	9.18e-05	0.00324	CbGpPWpGaD
Lansoprazole—Dysgeusia—Doxorubicin—sarcoma	9.16e-05	0.000409	CcSEcCtD
Lansoprazole—Malaise—Epirubicin—sarcoma	9.12e-05	0.000407	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—sarcoma	9.09e-05	0.000405	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—sarcoma	9.09e-05	0.000405	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—sarcoma	9.07e-05	0.000404	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—sarcoma	9.05e-05	0.000404	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—sarcoma	9.05e-05	0.000404	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—sarcoma	9e-05	0.000401	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	8.98e-05	0.00317	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	8.98e-05	0.00317	CbGpPWpGaD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—TP53—sarcoma	8.94e-05	0.00316	CbGpPWpGaD
Lansoprazole—Palpitations—Epirubicin—sarcoma	8.94e-05	0.000398	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—sarcoma	8.89e-05	0.000396	CcSEcCtD
Lansoprazole—ABCB1—lymph node—sarcoma	8.88e-05	0.00246	CbGeAlD
Lansoprazole—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	8.87e-05	0.00313	CbGpPWpGaD
Lansoprazole—Cough—Epirubicin—sarcoma	8.83e-05	0.000393	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—sarcoma	8.82e-05	0.000393	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	8.79e-05	0.0031	CbGpPWpGaD
Lansoprazole—Convulsion—Epirubicin—sarcoma	8.76e-05	0.000391	CcSEcCtD
Lansoprazole—Nausea—Etoposide—sarcoma	8.75e-05	0.00039	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—sarcoma	8.73e-05	0.000389	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—MYC—sarcoma	8.73e-05	0.00308	CbGpPWpGaD
Lansoprazole—Ill-defined disorder—Doxorubicin—sarcoma	8.68e-05	0.000387	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—sarcoma	8.65e-05	0.000386	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—sarcoma	8.61e-05	0.000384	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—sarcoma	8.61e-05	0.000384	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—sarcoma	8.61e-05	0.000384	CcSEcCtD
Lansoprazole—Agitation—Doxorubicin—sarcoma	8.6e-05	0.000383	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—sarcoma	8.58e-05	0.000383	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	8.56e-05	0.00302	CbGpPWpGaD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	8.55e-05	0.000381	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—EGFR—sarcoma	8.54e-05	0.00302	CbGpPWpGaD
Lansoprazole—Discomfort—Epirubicin—sarcoma	8.51e-05	0.000379	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	8.48e-05	0.003	CbGpPWpGaD
Lansoprazole—Malaise—Doxorubicin—sarcoma	8.44e-05	0.000376	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—sarcoma	8.42e-05	0.000375	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—sarcoma	8.41e-05	0.000375	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—sarcoma	8.39e-05	0.000374	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—sarcoma	8.38e-05	0.000373	CcSEcCtD
Lansoprazole—Confusional state—Epirubicin—sarcoma	8.32e-05	0.000371	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—sarcoma	8.27e-05	0.000369	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—sarcoma	8.25e-05	0.000368	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—sarcoma	8.25e-05	0.000368	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—sarcoma	8.23e-05	0.000367	CcSEcCtD
Lansoprazole—Infection—Epirubicin—sarcoma	8.2e-05	0.000366	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—sarcoma	8.17e-05	0.000364	CcSEcCtD
Lansoprazole—Shock—Epirubicin—sarcoma	8.12e-05	0.000362	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—sarcoma	8.11e-05	0.000361	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—sarcoma	8.1e-05	0.000361	CcSEcCtD
Lansoprazole—CYP1A1—Tryptophan metabolism—MDM2—sarcoma	8.09e-05	0.00286	CbGpPWpGaD
Lansoprazole—Thrombocytopenia—Epirubicin—sarcoma	8.08e-05	0.00036	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—sarcoma	8.08e-05	0.00036	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—KRAS—sarcoma	8.06e-05	0.00285	CbGpPWpGaD
Lansoprazole—Tachycardia—Epirubicin—sarcoma	8.06e-05	0.000359	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—sarcoma	8.02e-05	0.000357	CcSEcCtD
Lansoprazole—Hyperhidrosis—Epirubicin—sarcoma	7.98e-05	0.000356	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—sarcoma	7.97e-05	0.000355	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—sarcoma	7.97e-05	0.000355	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—sarcoma	7.97e-05	0.000355	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—sarcoma	7.94e-05	0.000354	CcSEcCtD
Lansoprazole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	7.94e-05	0.0028	CbGpPWpGaD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	7.91e-05	0.000353	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	7.88e-05	0.00278	CbGpPWpGaD
Lansoprazole—Discomfort—Doxorubicin—sarcoma	7.87e-05	0.000351	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—sarcoma	7.87e-05	0.000351	CcSEcCtD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	7.8e-05	0.00276	CbGpPWpGaD
Lansoprazole—Dry mouth—Doxorubicin—sarcoma	7.79e-05	0.000347	CcSEcCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—JUN—sarcoma	7.78e-05	0.00275	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—HRAS—sarcoma	7.75e-05	0.00274	CbGpPWpGaD
Lansoprazole—Hypotension—Epirubicin—sarcoma	7.71e-05	0.000344	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	7.7e-05	0.00272	CbGpPWpGaD
Lansoprazole—Confusional state—Doxorubicin—sarcoma	7.7e-05	0.000343	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—TP53—sarcoma	7.64e-05	0.0027	CbGpPWpGaD
Lansoprazole—Oedema—Doxorubicin—sarcoma	7.64e-05	0.000341	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—sarcoma	7.64e-05	0.000341	CcSEcCtD
Lansoprazole—Infection—Doxorubicin—sarcoma	7.59e-05	0.000338	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—sarcoma	7.52e-05	0.000335	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—sarcoma	7.51e-05	0.000335	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—sarcoma	7.49e-05	0.000334	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—sarcoma	7.48e-05	0.000333	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—sarcoma	7.47e-05	0.000333	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—sarcoma	7.45e-05	0.000332	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—sarcoma	7.42e-05	0.000331	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—sarcoma	7.41e-05	0.00033	CcSEcCtD
Lansoprazole—Hyperhidrosis—Doxorubicin—sarcoma	7.38e-05	0.000329	CcSEcCtD
Lansoprazole—Dyspnoea—Epirubicin—sarcoma	7.36e-05	0.000328	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—sarcoma	7.34e-05	0.000327	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—sarcoma	7.28e-05	0.000325	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	7.28e-05	0.00257	CbGpPWpGaD
Lansoprazole—Dyspepsia—Epirubicin—sarcoma	7.27e-05	0.000324	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	7.23e-05	0.00255	CbGpPWpGaD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	7.21e-05	0.00255	CbGpPWpGaD
Lansoprazole—Decreased appetite—Epirubicin—sarcoma	7.18e-05	0.00032	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—TP53—sarcoma	7.17e-05	0.00253	CbGpPWpGaD
Lansoprazole—Hypotension—Doxorubicin—sarcoma	7.14e-05	0.000318	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—sarcoma	7.13e-05	0.000318	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—sarcoma	7.12e-05	0.000317	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—sarcoma	7.06e-05	0.000315	CcSEcCtD
Lansoprazole—Pain—Epirubicin—sarcoma	7.06e-05	0.000315	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	7.03e-05	0.00248	CbGpPWpGaD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—sarcoma	6.96e-05	0.00031	CcSEcCtD
Lansoprazole—Insomnia—Doxorubicin—sarcoma	6.91e-05	0.000308	CcSEcCtD
Lansoprazole—ABCB1—Allograft Rejection—PDGFRA—sarcoma	6.86e-05	0.00242	CbGpPWpGaD
Lansoprazole—Paraesthesia—Doxorubicin—sarcoma	6.86e-05	0.000306	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—sarcoma	6.81e-05	0.000304	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—sarcoma	6.8e-05	0.000303	CcSEcCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—sarcoma	6.8e-05	0.0024	CbGpPWpGaD
Lansoprazole—Somnolence—Doxorubicin—sarcoma	6.79e-05	0.000303	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Epirubicin—sarcoma	6.75e-05	0.000301	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—sarcoma	6.72e-05	0.0003	CcSEcCtD
Lansoprazole—Decreased appetite—Doxorubicin—sarcoma	6.64e-05	0.000296	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—sarcoma	6.59e-05	0.000294	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—sarcoma	6.58e-05	0.000294	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—sarcoma	6.56e-05	0.000292	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—sarcoma	6.53e-05	0.000291	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—sarcoma	6.53e-05	0.000291	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—sarcoma	6.53e-05	0.000291	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—sarcoma	6.53e-05	0.000291	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	6.47e-05	0.00229	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	6.38e-05	0.00226	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	6.31e-05	0.00223	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—SRC—sarcoma	6.31e-05	0.00223	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Doxorubicin—sarcoma	6.29e-05	0.000281	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—sarcoma	6.25e-05	0.000278	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	6.14e-05	0.00217	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Epirubicin—sarcoma	6.08e-05	0.000271	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—sarcoma	6.07e-05	0.000271	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	6.07e-05	0.00214	CbGpPWpGaD
Lansoprazole—Body temperature increased—Doxorubicin—sarcoma	6.04e-05	0.000269	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—sarcoma	6.04e-05	0.000269	CcSEcCtD
Lansoprazole—Asthenia—Epirubicin—sarcoma	5.92e-05	0.000264	CcSEcCtD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	5.85e-05	0.00207	CbGpPWpGaD
Lansoprazole—Pruritus—Epirubicin—sarcoma	5.84e-05	0.00026	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—sarcoma	5.65e-05	0.002	CbGpPWpGaD
Lansoprazole—Diarrhoea—Epirubicin—sarcoma	5.65e-05	0.000252	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—sarcoma	5.63e-05	0.000251	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	5.53e-05	0.00195	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	5.53e-05	0.00195	CbGpPWpGaD
Lansoprazole—Asthenia—Doxorubicin—sarcoma	5.48e-05	0.000244	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—sarcoma	5.46e-05	0.000243	CcSEcCtD
Lansoprazole—Pruritus—Doxorubicin—sarcoma	5.4e-05	0.000241	CcSEcCtD
Lansoprazole—Vomiting—Epirubicin—sarcoma	5.25e-05	0.000234	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—sarcoma	5.23e-05	0.000233	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	5.22e-05	0.00184	CbGpPWpGaD
Lansoprazole—Rash—Epirubicin—sarcoma	5.2e-05	0.000232	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—sarcoma	5.2e-05	0.000232	CcSEcCtD
Lansoprazole—Headache—Epirubicin—sarcoma	5.17e-05	0.000231	CcSEcCtD
Lansoprazole—CYP1A2—Tryptophan metabolism—MDM2—sarcoma	5.16e-05	0.00182	CbGpPWpGaD
Lansoprazole—Dizziness—Doxorubicin—sarcoma	5.05e-05	0.000225	CcSEcCtD
Lansoprazole—Nausea—Epirubicin—sarcoma	4.9e-05	0.000219	CcSEcCtD
Lansoprazole—Vomiting—Doxorubicin—sarcoma	4.86e-05	0.000217	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—sarcoma	4.82e-05	0.000215	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—sarcoma	4.81e-05	0.000215	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—sarcoma	4.78e-05	0.000213	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	4.61e-05	0.00163	CbGpPWpGaD
Lansoprazole—Nausea—Doxorubicin—sarcoma	4.54e-05	0.000202	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	4.48e-05	0.00158	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	4.44e-05	0.00157	CbGpPWpGaD
Lansoprazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	4.29e-05	0.00152	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	4.21e-05	0.00149	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	4.02e-05	0.00142	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—SRC—sarcoma	4.02e-05	0.00142	CbGpPWpGaD
Lansoprazole—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	3.98e-05	0.00141	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	3.92e-05	0.00138	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	3.87e-05	0.00137	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—IL2—sarcoma	3.75e-05	0.00132	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	3.68e-05	0.0013	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—sarcoma	3.6e-05	0.00127	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	3.52e-05	0.00125	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	3.52e-05	0.00125	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	3.39e-05	0.0012	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—ENO2—sarcoma	3.36e-05	0.00119	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—HBA1—sarcoma	3.34e-05	0.00118	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	3.33e-05	0.00118	CbGpPWpGaD
Lansoprazole—ABCB1—Allograft Rejection—VEGFA—sarcoma	3.18e-05	0.00112	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—ENO2—sarcoma	2.94e-05	0.00104	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—HBA1—sarcoma	2.92e-05	0.00103	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PLCG1—sarcoma	2.85e-05	0.00101	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	2.83e-05	0.001	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	2.5e-05	0.000883	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PLCG1—sarcoma	2.49e-05	0.00088	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—ENO2—sarcoma	2.16e-05	0.000765	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—HBA1—sarcoma	2.15e-05	0.00076	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.07e-05	0.000731	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—ENO2—sarcoma	1.97e-05	0.000696	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—HBA1—sarcoma	1.96e-05	0.000691	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PLCG1—sarcoma	1.84e-05	0.000649	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	1.8e-05	0.000637	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	1.8e-05	0.000635	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	1.78e-05	0.00063	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PLCG1—sarcoma	1.67e-05	0.00059	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.61e-05	0.00057	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.57e-05	0.000555	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.45e-05	0.000511	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.41e-05	0.000499	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.34e-05	0.000472	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—ENO2—sarcoma	1.33e-05	0.000471	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—HBA1—sarcoma	1.32e-05	0.000468	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—ENO2—sarcoma	1.22e-05	0.000432	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—HBA1—sarcoma	1.21e-05	0.000429	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.19e-05	0.000419	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PLCG1—sarcoma	1.13e-05	0.0004	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—ENO2—sarcoma	1.09e-05	0.000385	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—HBA1—sarcoma	1.08e-05	0.000383	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—ENO2—sarcoma	1.06e-05	0.000376	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—HBA1—sarcoma	1.06e-05	0.000374	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PLCG1—sarcoma	1.04e-05	0.000366	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—ENO2—sarcoma	1e-05	0.000354	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—HBA1—sarcoma	9.97e-06	0.000352	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—ENO2—sarcoma	9.95e-06	0.000351	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—HBA1—sarcoma	9.88e-06	0.000349	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PLCG1—sarcoma	9.26e-06	0.000327	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PLCG1—sarcoma	9.03e-06	0.000319	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PLCG1—sarcoma	8.51e-06	0.000301	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—ENO2—sarcoma	8.5e-06	0.0003	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—HBA1—sarcoma	8.45e-06	0.000298	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PLCG1—sarcoma	8.44e-06	0.000298	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PLCG1—sarcoma	7.21e-06	0.000255	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—ENO2—sarcoma	6.56e-06	0.000232	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HBA1—sarcoma	6.52e-06	0.00023	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PLCG1—sarcoma	5.57e-06	0.000197	CbGpPWpGaD
